Delfi Diagnostics Stock
Delfi Diagnostics detects cancer early, when it is most curable, using high precision non-invasive blood tests.
Sign up today and learn more about Delfi Diagnostics Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Delfi Diagnostics Stock
Delfi Diagnostics detects cancer early, when it is most curable, using high-precision non-invasive blood tests. It uses artificial intelligence and genome sequencing to detect unique patterns of DNA fragmentation in the blood of patients. The company was founded in 2019 and is based in Baltimore, Maryland.
Investors
DFJ Growth
Avant, Hopin, DataRobot, Unity Technologies, Collective Health, Sysdig, Cohesity, Mapbox, Alchemy, Outreach
Menlo Ventures
Uber, Chime, Machine Zone, Getaround, BitSight, Recursion Pharmaceuticals, Outreach, Benchling, Synthego, Abnormal Security
Funding History
| August 2019 | $5.5M |
|---|---|
| January 2021 | $100M |
| July 2022 | $225M |
Management
Board Member
Justin Kao
Board Observer
Wouter Meuleman
Founder and CEO
Victor Velculescu
Chief Commercial Officer
Jessica Meng
Chief Scientific Officer
Nicholas Dracopoli
Senior Director, Genomic Science
Sian Jones
Chief Financial Officer
Doug Schenkel
Board of Directors
Victor Velculescu
Board Member
Greg Yap
Press
prnewswire - Jun, 5 2023
DELFI Diagnostics Hires David Morgenstern, PhD, as Vice President of Clinical Developmentgenomeweb - Jun, 3 2023
People in the News at Illumina, Pacific Biosciences, Myriad Genetics, Delfi Diagnostics, Moregenomeweb - Feb, 26 2023
People in the News at Natera, Delfi Diagnostics, Biocartis, Ansa Bio, Lex Diagnostics, Morenews - Dec, 19 2022
Funding Falls For Startups Fighting Cancerbizjournals - Oct, 7 2022
Leaders in Health Care 2022: Dr. Victor Velculescu, Delfi Diagnosticsprnewswire - Aug, 23 2022
Delfi Diagnostics Adds Finance and Market Access Leadership as It Prepares for Commercial Launchnews - Aug, 4 2022
The 10 Biggest Rounds Of July: Xpansiv Locks In Top Spot With $400M, Cleantech Monolith Lands Huge Roundlife-sciences-europe - Jul, 22 2022
Delfi Diagnostics–Allianz: investment, 202207 financing round Series B totalling $225m incl existing + co-investor AV8 Venturesbioworld - Jul, 20 2022
Future looks bright with Delfi Diagnostics’ $225M round for early cancer detection assayswsj - Jul, 19 2022
Delfi Diagnostics Gathers $225 Million for Cancer Blood Testsvcnewsdaily - Jul, 19 2022
Delfi Diagnostics Announces $225M Series Bbizjournals - Jul, 19 2022
Baltimore startup Delfi Diagnostics raises $225M with plans to change how lung cancer is diagnosedbiospace - Jul, 13 2022
Jessica Meng Joins Delfi Diagnostics as Chief Commercial Officerprnewswire - Jun, 22 2022
Delfi Diagnostics Appoints Jacob Van Naarden to its Board of Directorsprnewswire - Apr, 1 2022
Delfi Diagnostics Appoints Liz Homans to its Board of Directorsbizjournals - Mar, 30 2022
Former PGDx, Delfi Diagnostics CFO joins new cancer-detection startupbiospace - Oct, 8 2021
Doug Schenkel Joins Delfi Diagnostics as Chief Financial Officerbizjournals - Aug, 24 2021
Delfi Diagnostics' tech shows early success in detecting 90% of lung cancer casesbizjournals - Jun, 26 2021
Best in Tech Awards 2021delfidiagnostics - May, 31 2021
Delfi Diagnostics Begins Enrollment for Prospective Lung Cancer Screening Trial ahead of Planned Commercial Testfiercebiotech - Jan, 13 2021
Delfi Diagnostics raises $100M for a new approach to screening blood for cancerEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
